10-QPeriod: Q2 FY2026

Cigna Group Quarterly Report for Q2 Ended Jun 30, 2026

Filed July 30, 2026For Securities:CI

Summary

The Cigna Group reported solid financial results for the three and six months ended June 30, 2026. Total revenues increased by 7% and 6% respectively, driven by growth in pharmacy and fee-based services. Shareholders' net income saw a significant increase of 8% and 16%, respectively, primarily due to higher adjusted income from operations in the Cigna Healthcare segment and overall improved performance. The company's adjusted income from operations, a key non-GAAP metric, also demonstrated strength, growing 6% and 9% for the respective periods. This performance reflects effective management of medical costs, strategic pricing initiatives, and operational efficiencies across its business segments. Key financial developments include a notable increase in pharmacy revenues and a strong rebound in the Cigna Healthcare segment's profitability. While premiums decreased in the six-month period due to the HCSC transaction, this was offset by higher premium rates and growth in fee-based services. The company's liquidity remains robust, supported by operating cash flows and substantial committed credit facilities. Strategic optimization programs are progressing, contributing to efficiency improvements. The company also continued its capital return strategy through dividends and share repurchases.

Key Highlights

  • 1Total revenues increased by 7% to $71.7 billion for the three months ended June 30, 2026, and by 6% to $140.2 billion for the six months ended June 30, 2026.
  • 2Shareholders' net income rose by 8% to $1.66 billion for the three months and 16% to $3.31 billion for the six months ended June 30, 2026.
  • 3Adjusted income from operations, a key non-GAAP metric, increased by 6% for the three months and 9% for the six months ended June 30, 2026.
  • 4Pharmacy revenues showed strong growth, increasing by 7% and 9% for the respective periods, driven by changes in claims composition.
  • 5Cigna Healthcare segment's pre-tax adjusted income from operations saw a significant increase of 17% for both the three and six month periods.
  • 6The company's debt-to-capitalization ratio remained stable at 42.8% as of June 30, 2026, indicating a sound capital structure.
  • 7Cash flow from operating activities significantly improved, turning positive at $710 million for the six months ended June 30, 2026, compared to $34 million in the prior year.

Frequently Asked Questions

Revenue growth was primarily driven by increases in Pharmacy revenues, up 7% due to changes in claims composition, and growth in fee-based services within Cigna Healthcare and Evernorth Health Services segments. Premiums also saw an increase, largely due to higher premium rates in the Cigna Healthcare segment.

The company effectively managed medical costs and benefit expenses. For the three months ended, medical costs and other benefit expenses increased by 9%, reflecting higher medical costs within Cigna Healthcare. However, for the six months ended, these costs decreased by 10%, largely due to the impact of the HCSC transaction, partially offset by higher medical costs. The company's medical care ratio remained relatively stable overall.

The provided filing does not include specific forward-looking guidance for the remainder of the year. However, the strong performance in the first half of 2026 suggests a positive trajectory, though management advises caution when estimating full-year results based on interim performance due to seasonal factors and market conditions.

The Cigna Group continues to return capital to shareholders through the payment of regular quarterly dividends and share repurchases. The company repurchased 0.9 million shares for approximately $250 million during the six months ended June 30, 2026.